Photo of Adam Nicolais

The Federal Circuit recently reversed a District of Delaware decision that invalidated claims of Novartis’s Orange Book listed patent, U.S. Patent No. 8,101,659 (the “’659 patent”), for its blockbuster drug Entresto®, a combination drug used to treat heart failure.

Following a three-day bench trial, Judge Andrews found the ’659 patent not invalid for obviousness, lack